Oral Biologics & Biosimilars Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

Spread the love

The Oral Biologics & Biosimilars by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Oral Biologics & Biosimilars Market:
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

According to The Business Research Company’s Oral Biologics & Biosimilars, The oral biologics & biosimilars market size has grown exponentially in recent years. It will grow from $6471.49 billion in 2023 to $7788.01 billion in 2024 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to increased collaboration and partnerships between market players for better insights, increased need for immunology, increased demand due for cost-effective manufacturing process, aging population, government initiatives, and the ability to command high prices.

The oral biologics & biosimilars market size is expected to see exponential growth in the next few years. It will grow to $16634.59 billion in 2028 at a compound annual growth rate (CAGR) of 20.9%. The growth in the forecast period can be attributed to robust research and development activities for development of oral biologics, lean towards pills over injections, adoption of unhealthy lifestyles, technological advances, ease of use of oral biologics, increase in healthcare access, reimbursement of biologics, rise in biosimilars, and rising prevalence of chronic diseases . Major trends in the forecast period include invest in the oral biologics market to benefit from potentially strong profit margins, shift to biologics, as the innovation rate is increasing in that field, develop microneedle injectors-based drugs to increase the bioavailability and eliminate side effects of subcutaneous route.

The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to propel the growth of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases. Biologics stimulate the immune system’s attack on cancer cells, aiding the body’s natural defenses in getting rid of the disease-causing cells. According to a United Nations article, a US-based intergovernmental organization, by 2030, chronic diseases are predicted to account for 70% of all fatalities worldwide. It is anticipated that chronic disease will account for nearly 60% of all deaths worldwide. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the biologics and biosimilar market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies
2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The creation of new insulin biosimilar is a key trend gaining popularity in the oral biologics and biosimilar market. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin to capture the market share. For instance, in November 2021, Biocon, an India-based biopharmaceutical company launched inter-changeable biosimilar insulin. These products help to control high blood sugar in pediatric patients with type 1 diabetes and adults with type 2 diabetes and are available in a vial and prefilled pen presentations. These are interchangeable for the reference brand, Lantus (insulin glargine), allowing for substitution at the pharmacy counter. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.

The oral biologics & biosimilars market report table of contents includes:

1. Executive Summary
2. Oral Biologics & Biosimilars Market Characteristics
3. Oral Biologics & Biosimilars Market Trends And Strategies
4. Oral Biologics & Biosimilars Market analysis
5.Oral Biologics & Biosimilars Market Size And Growth
6. Oral Biologics & Biosimilars Segmentation
7. Oral Biologics & Biosimilars Regional And Country Analysis
.
.
.
27.Oral Biologics & Biosimilars Competitive Landscape And Company Profiles
28. Oral Biologics & Biosimilars Key Mergers And Acquisitions
29.Oral Biologics & Biosimilars  Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

  •  Merck & Co. Inc.
  • GlaxoSmithKline
  • Novo Nordisk
  • ALK-Abelló
  • Aimmune Therapeutics Inc.
  • VIVUS Inc.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →